Plant-derived exosome-like nanovesicles (PELNs) and their therapeutic activities: Current insights and future prospects

IF 6.7 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology Pub Date : 2026-01-01 Epub Date: 2026-06-26 DOI:10.1016/j.crbiot.2026.100406

Lin Lat La Min, Do Thi Cat Tuong, Smirnova Elena, Dong I. Lee, Adhimoolam Karthikeyan, Taesun Min

{"title":"Plant-derived exosome-like nanovesicles (PELNs) and their therapeutic activities: Current insights and future prospects","authors":"Lin Lat La Min, Do Thi Cat Tuong, Smirnova Elena, Dong I. Lee, Adhimoolam Karthikeyan, Taesun Min","doi":"10.1016/j.crbiot.2026.100406","DOIUrl":null,"url":null,"abstract":"<div><div>Plant-derived exosome-like nanovesicles (PELNs), ranging from 30 to 200 nm, are lipid bilayer membrane nanovesicles isolated from plant tissues that are structurally similar to mammalian exosomes. PELNs contain miRNAs, proteins, lipids, and secondary metabolites that contribute to their diverse therapeutic activities. Due to their easy availability, low immunogenicity, high biocompatibility, relative safety and cost-effectiveness, PELNs are promising therapeutic modalities and drug encapsulation and delivery. Recent studies have highlighted the potential of PELNs to enter cells, modulate cellular activities, and treat various diseases, including inflammation, obesity, and cancer in preclinical models. Despite these encouraging outcomes, standardized methods for PELNs isolation and purification methods are lacking, and the mechanisms governing their cellular uptake and therapeutic effects remain unclear. This review discusses recent developments in PELNs-related research, focusing on disease treatment, underlying mechanisms, and highlights research gaps and future prospects for clinical translation.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"12 ","pages":"Article 100406"},"PeriodicalIF":6.7000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262826000420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Plant-derived exosome-like nanovesicles (PELNs), ranging from 30 to 200 nm, are lipid bilayer membrane nanovesicles isolated from plant tissues that are structurally similar to mammalian exosomes. PELNs contain miRNAs, proteins, lipids, and secondary metabolites that contribute to their diverse therapeutic activities. Due to their easy availability, low immunogenicity, high biocompatibility, relative safety and cost-effectiveness, PELNs are promising therapeutic modalities and drug encapsulation and delivery. Recent studies have highlighted the potential of PELNs to enter cells, modulate cellular activities, and treat various diseases, including inflammation, obesity, and cancer in preclinical models. Despite these encouraging outcomes, standardized methods for PELNs isolation and purification methods are lacking, and the mechanisms governing their cellular uptake and therapeutic effects remain unclear. This review discusses recent developments in PELNs-related research, focusing on disease treatment, underlying mechanisms, and highlights research gaps and future prospects for clinical translation.

Abstract Image

查看原文本刊更多论文

植物源性外泌体样纳米囊泡（peln）及其治疗活性：目前的见解和未来展望

植物源性外泌体样纳米囊泡（PELNs）是一种从植物组织中分离出来的脂质双层膜纳米囊泡，其结构与哺乳动物外泌体相似，粒径在30 ~ 200 nm之间。peln含有mirna，蛋白质，脂质和次级代谢物，有助于其多样化的治疗活性。由于其易于获得、低免疫原性、高生物相容性、相对安全性和成本效益，peln是很有前途的治疗方式和药物包封和递送。最近的研究强调了peln在临床前模型中进入细胞、调节细胞活动和治疗各种疾病（包括炎症、肥胖和癌症）的潜力。尽管取得了这些令人鼓舞的结果，但目前缺乏peln分离和纯化的标准化方法，并且控制其细胞摄取和治疗效果的机制仍不清楚。本文综述了pelns相关研究的最新进展，重点关注疾病治疗、潜在机制，并强调了研究空白和临床转化的未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology

CiteScore

6.70

自引率

3.60%

发文量

审稿时长

38 days

期刊介绍： Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines. Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.